Login to Your Account



Omeros Goes Down Hard After Blowing Out ACL Trial

By Tom Wall


Monday, April 4, 2011
Omeros Corp. went down hard following news that the Seattle-based company's lead candidate OMS103HP did not meet endpoints in Phase III trials evaluating its ability to improve postoperative joint motion and function and reduce postoperative pain in patients who'd undergone arthroscopic anterior cruciate ligament (ACL) reconstruction surgery.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription